CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 303 enrolled
Drug / intervention
positron emission tomography +2 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00004138
NCT00004138N/ACompleted
CompareCT.gov

The Utility of Positron Emission Tomography (PET) in Staging of Patients With Potentially Operable Non-Small Cell Lung Carcinoma

Alliance for Clinical Trials in Oncology·interventional·Posted Jan 27, 2003·Updated Jul 13, 2016

In Brief

A clinical study evaluating positron emission tomography, radionuclide imaging, and 1 other intervention for Lung Cancer. Completed, enrolled 303 participants across 23 sites.

Detailed Summary

RATIONALE: Imaging procedures, such as positron emission tomography (PET), may improve the ability to detect the extent of non-small cell lung cancer. PURPOSE: Diagnostic trial to study the effectiveness of PET for detecting lesions in patients who have newly diagnosed stage I, stage II, or stage IIIA non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartSep 1, 1999
Primary CompletionDec 1, 2002
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 23.4 years ago

Interventions

positron emission tomographyprocedure

radionuclide imagingprocedure

fludeoxyglucose F 18radiation